Marlo Blazer - Concepedia

Author

Marlo Blazer

Millennium Engineering and Integration (United States)

Also Known As

M Blazer, M. A. Blazer, M. Blazer, Marlo A. Blazer, Marlo Blazer

Publications

815

Citations

H-Index

Concepts

All Affiliations

Millennium Engineering and Integration (United States)The Ohio State University The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Takeda (United States)Icahn School of Medicine at Mount Sinai

About

Marlo Blazer is an author at Millennium Engineering and Integration (United States) specializing in oncology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	395
2	Health Sciences	3	3	69
3	Public Health	1	1	37
4	Blood Transplantation	1	1	37
5	Classical Hematology	1	1	37

Marlo Blazer

Publications

746

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas Marlo Blazer, Christina Wu, Richard M. Goldberg, Annals of Surgical Oncology Surgical OncologyLocally Advanced UnresectablePancreatic CancerGastrointestinal OncologyMedicine	2014	249
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma Ajai Chari, Dorothy Romanus, Antonio Palumbo, Clinical Lymphoma Myeloma & Leukemia	2019	104
A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis Daniel H. Ahn, Kavya Krishna, Marlo Blazer, Therapeutic Advances in Medical Oncology	2016	53
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd Ajai Chari, Paul G. Richardson, Dorothy Romanus, Expert Review of Hematology	2020	43
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, Clinical Lymphoma Myeloma & Leukemia	2018	42
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies Parameswaran Hari, Dorothy Romanus, Katarina Luptakova, Journal of Geriatric Oncology	2017	38
Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States Jill A. Bell, Aaron Galaznik, Eileen Farrelly, Leukemia Research Elderly PatientsHospital MedicineHematological MalignancyMyeloid NeoplasiaAcute Myeloid Leukemia	2018	37
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US Faith E. Davies, Robert M. Rifkin, Caitlin Costello, Annals of Hematology	2021	32
Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases Ludmila Katherine Martin, Anthony Cucci, Lai Wei, Clinical Colorectal Cancer HepatologyGastrointestinal OncologyYttrium-90 RadioembolizationMedicineColorectal Cancer	2012	29
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy Candice M. Wenzell, Michael Berger, Marlo Blazer, Supportive Care in Cancer Emetogenic ChemotherapyOncologyMedicineMetronomic TherapyClinical Trials	2013	25

Page 1